Business
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Launching with hearty Series A rounds, these new companies are ready to run.
A little more than one year after Gilead Sciences and Galapagos NV announced intentions to seek regulatory approval for Jyseleca (filgotinib) as a treatment for rheumatoid arthritis, the companies have pulled the plug on that goal.
A roundup of life sciences companies raking in the cash.
Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.
Clinical-stage biotechnology company Allogene Therapeutics and start-up company Overland Pharmaceuticals are forming a new joint company named Allogene Overland Biopharm.
Mergers and acquisitions are a well-known fact in the life sciences industry, and anyone working within the sector knows to expect them at any time.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 15, 2020.
Robert Coughlin announced in an open letter on Monday that he is leaving the Massachusetts Biotechnology Council (MassBio) following a 13-year tenure as the organization’s president and CEO.
San Diego-based Locanabio secured $100 million in a Series B financing round that will be used to advance the company’s portfolio of novel RNA-targeted gene therapies for neurodegenerative, neuromuscular and retinal diseases.
Relay Therapeutics announced today that it has entered a global license and collaboration agreement with Genentech for the commercialization and development of RLY-1971.